CARsgen Therapeutics (HKG:2171) reported 75.5 million yuan in attributable loss for the half ended June 30, narrowing from a loss of 351.6 million yuan in the year-ago period, according to a Hong Kong bourse filing on Thursday.
Loss per share was 0.14 yuan, compared with 0.63 yuan in the prior year.
Revenue for the period jumped to 51 million yuan from 6.3 million yuan, figures showed.